CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

SIMPLE SUMMARY: CX-5461 is an RNA polymerase I inhibitor that is in clinical trials for both advanced hematological cancers and solid tumors. Experimentally, this drug has been shown to induce a p53-independent DNA damage response through ATM and ATR kinase, and has particular activity against chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cornelison, Robert, Biswas, Kuntal, Llaneza, Danielle C., Harris, Alexandra R., Sosale, Nisha G., Lazzara, Matthew J., Landen, Charles N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/
https://www.ncbi.nlm.nih.gov/pubmed/34680204
http://dx.doi.org/10.3390/cancers13205056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533980/
https://www.ncbi.nlm.nih.gov/pubmed/34680204
http://dx.doi.org/10.3390/cancers13205056

Ejemplares similares